Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
Charlie Zhou, Head of Portfolio Strategy at Ouro Medicines, shared a post on LinkedIn about the recent article he and his colleagues co-authored, adding:
“It’s been a privilege to collaborate with some of the preeminent experts in autoimmune cytopenias on this review examining the potential of immune reset therapies to change the treatment landscape for these debilitating conditions.”
Title: Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
Authors: David J. Kuter, Sigbjørn Berentsen, Nichola Cooper, Lei Zhang, Jun Shi, Yunfei Chen, Lele Zhang, Charlie Zhou, Yanrong Wang, Jaideep S. Dudani, Neelufar Mozaffarian
Read the Full Article on Blood Reviews
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 13:04Ben Samelson-Jones: Do Gene Variants Drive PK Differences in FIX-Fusion and N9-GP Therapies?
-
Sep 23, 2026, 12:57Shelly Reed: Advocating for HTCs and CDC Funding with the Hemophilia Federation of America
-
Sep 23, 2026, 12:51Domenico Girelli: How Verona Hospital Transformed ED Anemia Care with Patient Blood Management
-
Sep 23, 2026, 12:45Lina Camacho-Arteaga: ENTIS Study Uncovers Safety Data on Early Pregnancy Exposure to Direct Oral Anticoagulants
-
Sep 23, 2026, 12:34Hiteshi K.C. Chauhan: Why Mechanical Valve Thrombosis Is a Systems Failure, Not Just an Anticoagulation Error
-
Sep 23, 2026, 12:33World Thrombosis Day 2026 Puts Women’s Health in Focus – JTH
-
Sep 23, 2026, 12:30Zain Khalpey: How a Sudden Blockage Causes Myocardial Infarction
-
Sep 23, 2026, 12:16Apurva Popat: When Heparin Triggers Thrombosis
-
Sep 23, 2026, 12:14Zahra Ghasemi: The Power of Voluntary Blood Donation